La sumidad florida del espino blanco en terapéutica ... - Fitoterapia.net

More documents

Recommendations

Info

20 Revista de Fitoterapia 2004; 4 (1): 5-21 14. Müller A, Linke W, Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocites. Planta Med 1999; 65: 335-9. 15. Garjani A, NazemiyehH, Maleki N. Effects of extracts fro m flowering tops of Crataegus meyeri A. Pojark. On ischaemic arrhytmias in anaesthetized rats. Phytoter Res 2000; 14: 428- 3 1 . 16. Al Makdessi S, Sweidan H, Dietz K, et al. Protective eff e c t of Crataegus oxyacantha against re p e rfusion arrhythmias after global no-flow ischemia in the rat heart. Basic Res Card i o l 1999; 94: 71-7. 17. Gaudel Y, Duvelleroy MA. Role of oxygen radicals in card i a c injury due to reoxygenation. J Mol Cell Cardiol 1984; 16: 459- 4 7 0 . 18. Middleton E. Effect of plant flavonoids on immune and inflammatory cell function. Flavonoids in the living system. Edit by Manthey and Busling Plenum Press. 1998. 19. Middleton E, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 1992¸43: 1167-1179. 20. Chatterjee SS, Koch E, Jaggy H et al. In-vitro-und in-vivountersuchungen zur kard i o p rotektiven wirkung von oligomere n p rocyanidinen in einem crataegus-extrakt aus blättern mit blüten. Arzniem.-Forsch./Drug Res 1997; 47: 821-5. 21. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995; 49: 57-68 22. Ying QL; Rinehart AR, Simon SR, et al. Inhibition of human leucocyte elestase by ursolic acid. Biochem J 1991; 277: 521-6. 23. Löser B, Kruse SO, Melzig MF, et al. Inhibition of neutro p h i l elastase activity by cinnamic acid derivatives from cimicifuga racemosa. Planta Med 2000; 66: 751-3. 24. Ahumada C, Saenz T, García D, et al. The effects of a triterpene fraction isolated from Crataegus monogyna Jacq. On d i ff e rent acute inflammation models in rats and mice. Leucocyte migration and phospholipase A2 inhibition. J Pharm Pharmacol 1997; 49: 329-31. 25. Wiklund O, Hulthe G, Bondjers G et al. Cell adhesion molecules and secretory type II phospholipase A2 in relation to carotid athero s c l e rosis in patients with hyperc h o l e s t e rolemia. J Intern Med 2001; 249: 441-449. 26. Zhou C, Sun X, Liu W.et al. Effects of oleanolic acid on the immune complex allergic reaction and inflammation. J Clin Pharmacol Sci 1993; 2: 69-79. 27. Najid A, Simon A, Cook J, et al. Characterization of ursólic acid as a lipoxygenase and ciclooxigenase inhibitor using m a c rophages, platelets and diff e rentiated HL60 leukemic cells. FEBS letters 1992; 299: 213-7. 28. Shahat AA, Hammouda F, Ismail SI, et al. Anti-complementary activity of Crataegus sinaica. Planta Med 1996; 62: 10-3. Tsai SH, Liang YCH, Shiau SL, et al. Suppresion of TNFa-mediated NF-κB activity by myricetin and other flavonoids thro u g h d o w n regulating the activity of IKK in ECV304 cells. J Cell Biochem 1999; 74: 606-15. 29. Nardini M, Leonardi F, Scaccini C, et al. Modulation of ceramide-induced NF-κB binding activity and apoptotic response by c a ffeic acid in U937 cells: comparison with other antioxidants. F ree Rad Biol Med 2000; 30: 722-33. 30. Lonn E, Yusuf S, Dzavik V, et al Effects of ramipril and vitamin E on athero s c l e rosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E. C i rculation 2001; 103: 919-25. 31. Brown BG, Zhao XQ, Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Eng J Med 2001; 345: 1583-92. 32. Diplock AT, Charleux JL, Cro z i e r - Willi G, et al. Functional food science and defence against reactive oxidative species. Br J Nutr 1998; 80: s77-s112. 33. Nagata H, Takekoshi S, Takagi T, et al. Antioxidative action of flavonoids, quercetin and catechin, mediated by the activation of glutathione peroxidase. Tokai J Exp Clin Med; 24: 1-11. 34. De Groot H, Rauen U. Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam Clin Pharmacol 1998; 12: “49-55. 35. Rakotoarison DA, Gressier B, Trotin F et al. Antioxidant activities of polyphenolic extracts from flowers, in vitro callus and cell suspension cultures of Crataegus monogyna. Pharmazie 1997; 52: 60-3. 36. Bahorun T, Trotin F, Pommery J, et al. Antioxidant activities of Crataegus monogyna extracts. Planta Med 1994; 60: 323-8. 37. Zhang Z, Chang Q, Huang Y, et al. Characterization of antioxidants present in hawthorn fruits. J Nutr Biochem 2001; 12: 1 4 4 - 5 2 . 38. Quettier-Deleu C, Voiselle G, Fruchart JC, et al. Hawthorn inhibits LDL oxidation. Pharmazie 2003; 58: 577-81. 39. Schüssler M, Hölzl J, Rump AF, et al. Functional and antiischaemic effects of monoacetyl-vitexinrhamnoside in diff e rent in v i t ro models. Gen Pharmacol 1995; 26: 1565-70. 40. Petkov V. Plants with hypotensive, antiatheromatous and c o ronariodilating action. Am J Chin Med 1979; 7: 197-236. 41. Schüssler M, Hölzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995; 45: 842-5. 42. Hansen K, Nyman U, Wagner Smitt U, et al. in vitro scre ening of traditional medicines for anti-hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). 43. Ta u c h e rt M, Ploch M, Hübner WD. Wirksamkeit des We i s sdorn-extraktes LI 132 im vergleich mit captopril. Münch Med Woch 1994; 136: S27-S33. 44. Inokuchi JK, Okabe H, Yamauchi T, et al. Inhibitors of angiotensin converting enzyme in crude drugs. Chem Pharm Bull 1984; 32: 3615-3619. 45. Kim SH, Kang KW, Kim KW et al. Procyanidins in Crataegus extract evoke endothelium-dependent vasorelaxation in rat a o rta. Life Sci 2000; 67: 121-31. 46. Al Makdessi S, Sweidan H, Müllner S, et al. Myocardial protection by pre t reatment with Crataegus oxyacantha. Arz n e i m . - Forsch./ Drug Res 1996; 46:25-27. 47. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rar cardiomyocites during hypoxia and reoxigenation. J Moll Cell Cardiol 1994; 26: 949-58. 48. Veveris M, Koch E, Chaterjee SS. Crataegus special extract WS(R) 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and re p e rf u s i o n . Life Sci 2004; 27: 1945-55 49. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre t re a t m e n t with clopidogrel and aspirine followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33. 50. McKay RG, Boden WE. Small peptide GP Iib/IIIa re c e p t o r inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Card i o l 2001; 16: 364-9.
Revista de Fitoterapia 2004; 4 (1): 5-21 51. Vibes J, Lasserre B, Gleye J, Declume C. Inhibition of t h romboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads. Pro s t a g l a ndins Leukot Essent Fatty Acids 1994;50:173-175. 52. Rogers KL, Grice ID, Griffiths LR Inhibition of platelet aggregation and 5-HT release by extracts of Australian plants used traditionally as headache treatments. Eur J Pharm Sci 2 0 0 0 ; 9 : 3 5 5 - 3 6 3 . 53. Yun-Choi HS, Kim SO, Kim JH, et al. Modified smear method for screening potential inhibitors of platelet aggre g ation from plant sources. J Nat Prod 1985; 48: 363-70. 54. Borrelli F, Izzo AA. The plant kingdom as a source of antiulcer remedies. Phytother Res 2000; 14: 581-91. 55. Rose DP, Boyar AP, Winder EL. International comparison of m o rtality rates for cancer of the breast, ovary, prostate and colon and per capita fat consumption. Cancer 1986; 58: 2363- 2 3 7 1 . 56. Joussen AM, Rohrschneider K, Reichling J, et al. Tre a t m e n t of corneal neovascularization with dietary isoflavonoids and flavonoids Exp Eye Res 2000; 71: 483-7. 57. Ficarra P, Ficarra R, De Pasquale A, et al High-perf o r m a nce liquid chromatography of flavonoids in Crataegus oxyacantha L. Il Farmaco 1990; 45: 247-55. 58. Paper DH. Natural products as angiogenesis inhibitors Planta Med 1998; 64:686-695. 59. Min BS, Kim YH, Lee SM, et al. Cytotoxic triterpenes fro m Crataegus pinnatifida. Arch Pharm Res 2000; 23:155-8. 60. Griffiths DW, Robertson GW; Shepherd T. A comparison of the composition of epicuticular wax from red raspberry (Rubus idaeus L) and hawthorn (Crataegus monogyba Jacq.) flowers. Phytochemistry 2000; 55: 11-6. 61. Fotsis T. Phytoestrogens and inhibition of angiogénesis. Baill Clin End Metabol 1998;12:649-67. 62. Huang YT, Kuo ML, Liu JY,et al. Inhibition of protein kinase C and proto-oncogene expression in NIH 3T3 cells by apigenin. Eur J Cancer 1996; 32: 146-51. 63. Eichstadt H, Bader M, Danne O, et al. Crataegus-Extrakt hilft dem patienten mit NYHA II-herz i n s u ffizienz. Therapiewoche 1989; 39: 3288-96. 64. Loew D, Crataegus-spezialextrakte bei herz i n s u ff i z i e n z . G e s i c h e rte pharmakologische und klinische ergebnisse. Kass e n a rtz 1994; 15: 43-52. 65. Ta u c h e rt M,Gildor A, Lipinsky J. High-dose Crataegus(hawthorn) extract WS 1442 for the treatment of NYHA class II heart f a i l u re patients. Herz 1999; 24: 465-474. 66. O´Conolly M, Jansen W, Bernhoft G et al. Treatment of d e c reasing cardiac performance in advanced age with stand a rdized Crataegus extract. Fortschr Med 1986;104:805-8. 67. Bodigheimer K, Chase D. Effectiveness of Hawthorn extract at a dosage of 3x100 mg per day. Multicentre double-blind trial with 85 NYHA stage II heart failure patients. Munch Med Wochenschr 1994; 136: S7-11. 68. Schmidt U, Kuhn U, Ploch M et al. Efficacy of the hawthorn extract LI 132 (600 mg/d) during eight weeks treatment. Plac e b o - c o n t rolleed double-blind trial with 78 NYHA stage II heart f a i l u re patients. Munch Med Wochenschr 1994; 136: S13-9. 69. Forster A, Forster K, Buhring M et al. Crataegus for moderately reduced left ventricular ejection fraction. Erg o s p i ro m e t r i c monitoring study with 72 patients in a double-blind comparison with placebo. Munch Med Wochenschr 1994; 136: S21-6. 70. Weikl VA, Assmus KD, Neukum-Schmidt, et al. Objective confirmation of the efficacy of a Crataegus-specialextrakt (a special Crataegus extract) WS 1442 in patients with card i a c i n s u fficiency (NYHA II). Fortschr Med 1996; 114: 291-6. 71. Ta u c h e rt M Ploch M, Hubner WD. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Multicenter double-blind study with 1432 NYHA stage II heart f a i l u re patients. Munch Med Wochenschr 1994; 136: S27-33. 72. Leuchtgens H. Crataegus special extract WS 1442 in NYHA II heart Failure: a Placebo controlled randomized doubleblind study. Forts Med 1993; 111: 352-4. 73. Iwamoto M Sato T, Ishizaki T. Clinical effect of crataeggut in ischemic heart disease and/or hypertensive origin. Planta Med 1981; 42: 1-16. 74. Eiff M, Brunner H, Haegeli A, et al. Hawthorn/passion flower extract and improvement in physical exercise capacity of patients with dyspnea class II of the NYHA functional classification. Acta Ther 1994; 20: 47-63. 75. Ta u c h e rt M. Efficacy and safety of a Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002; 143: 910-5. 76. Schroder D, Weisser M, Klein P. Efficacy of a homeopathic Crataegus preparation compared with usual therapy for mild (NYHA II) cardiac insufficiency: results of an observacional c o h o rt study. Eur J Heart Fail 2003; 5: 319-26. 77. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for tre ating chronic heart failure; meta-analysis of randomized trials. Am J Med 2003; 114: 665-74. 78. Holubarsch CJF, Colucci WS, Meinertz T, et al. Survival and p rognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE)-rationale, study design and study p rotocol. Eur J Heart Fail 200; 2: 431-7. 79. Rose J, Treadway S. Herbal support for a healthy card i ovascular system. Clin Nutr Ins 1999; 6: 1-6 80. Rigelsky J, Sweet B. Hawthorn: pharmacology and therapeutic uses. Am J Health-Syst Pharm 2002; 59:417-22. 81. Fong HH, Bauman JL. Hawthorn. J Cardiovasc Nurs 2002; 16: 1-8 82. Hanak Th, Brückel MH. Behandlung von leichten stabilen formen der angina pectoris mit Crataegutt ® novo. Eine placebo k o n t ro l i e rte Doppelblindstudie. Terapiewoche 1983;33: 4331-3. 83. Weng WL. Therapeutic effect of Crataegus pinnatifida on 46 cases of angina pectoris-a double blind study. J Tradit Chin Med 1984;4: 293-4. 84. Dalli E. Treatment of stable angina pectoris with hawthorn (Crataegus oxyacantha). Heart 2002; 87 (suppl I), A9. 85. Walker AF, Marakis G; Morris AP, Robinson PA. Pro m i s i n g double-blind pilot study of mild, essential hypertension. Phytother Res 2002; 16: 48-54. 86. Chen JD, Wu YZ, Tao ZL et al. Hawthorn (shan za) drink and its lowering effect on blood lipids levels in humans and rats. World Rev Nutr Diet 1995; 77: 147-154. 87. Di Renzi L, Cassone R, Lucisano V, Leggio F, Gambelli G. Sull´impiego di estratti iniettabili di Crataegus nella terapia dei disturbi del circolo arterioso periferico in soggeti con art e r i opatía obliterante degli arti inferiori. Boll Soc Ital Cardiol 1968; 14: 577-584). 88. Blumenthal M, Busse WR, Goldberg A et al. The Complete German Commision E monographs: therapeutics guide to herbal medicines. 1st Ed.Austin (Texas)). American Botanical Council 1998; 142: 333-5. 89. European Scientific Cooperative On Phytotherapy. ESCOP monographs. The scientific foundation for herbal medicinal products. 2ª ed., Stuttgart: Thieme, 2003. 21
Page 1 and 2: Revista de Fitoterapia 2004; 4 (1):
Page 15: Revista de Fitoterapia 2004; 4 (1):

La sumidad florida del espino blanco en terapéutica ... - Fitoterapia.net

Create successful ePaper yourself

Delete template?

Save as template?